Schiffer R B, Wineman N M
Department of Psychiatry, University of Rochester Medical Center.
Am J Psychiatry. 1990 Nov;147(11):1493-7. doi: 10.1176/ajp.147.11.1493.
In a double-blind clinical trial involving 28 patients with multiple sclerosis and major depressive disorder, 14 patients were randomly assigned to a 5-week trial of desipramine and individual psychotherapy and 14 to placebo plus psychotherapy. Clinical judgments indicated that patients treated with desipramine improved significantly more than the placebo group. This was confirmed by scores on the Hamilton Rating Scale for Depression but not by Beck Depression Inventory scores. Side effects limited desipramine dosage in half of the treated patients. The authors conclude that desipramine has a modest beneficial effect in serious depression associated with multiple sclerosis but that side effects may be more of a limiting factor than in patients without medical or neurologic disease.
在一项涉及28名患有多发性硬化症和重度抑郁症患者的双盲临床试验中，14名患者被随机分配接受为期5周的去甲丙咪嗪治疗及个体心理治疗，另外14名患者接受安慰剂加心理治疗。临床判断表明，接受去甲丙咪嗪治疗的患者比安慰剂组改善明显更多。这一点通过汉密尔顿抑郁量表评分得到证实，但贝克抑郁量表评分未证实。副作用使一半接受治疗的患者限制了去甲丙咪嗪的剂量。作者得出结论，去甲丙咪嗪在与多发性硬化症相关的严重抑郁症中有适度的有益作用，但副作用可能比没有医学或神经疾病的患者更具限制因素。
